Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report)'s stock price fell 10.2% during mid-day trading on Tuesday . The company traded as low as $17.83 and last traded at $17.87. 403,603 shares traded hands during trading, an increase of 134% from the average session volume of 172,190 shares. The stock had previously closed at $19.89.
Analyst Ratings Changes
A number of research firms recently issued reports on TYRA. Bank of America upgraded Tyra Biosciences from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $22.00 to $31.00 in a research note on Friday, October 18th. HC Wainwright boosted their price objective on Tyra Biosciences from $30.00 to $32.00 and gave the company a "buy" rating in a research note on Monday. Wedbush reiterated an "outperform" rating and set a $28.00 price objective on shares of Tyra Biosciences in a research note on Friday. Piper Sandler assumed coverage on Tyra Biosciences in a research note on Thursday, August 15th. They set an "overweight" rating and a $33.00 price objective on the stock. Finally, Oppenheimer boosted their target price on Tyra Biosciences from $25.00 to $33.00 and gave the stock an "outperform" rating in a research report on Thursday, September 19th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $31.40.
Check Out Our Latest Research Report on TYRA
Tyra Biosciences Trading Down 15.0 %
The business has a fifty day moving average price of $22.84 and a 200-day moving average price of $19.91. The stock has a market capitalization of $893.02 million, a PE ratio of -9.80 and a beta of 1.01.
Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.41) by $0.09. On average, equities analysts anticipate that Tyra Biosciences, Inc. will post -1.53 earnings per share for the current fiscal year.
Insider Transactions at Tyra Biosciences
In related news, CEO Todd Harris sold 10,092 shares of the stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $24.13, for a total transaction of $243,519.96. Following the completion of the sale, the chief executive officer now directly owns 1,479,528 shares in the company, valued at $35,701,010.64. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In the last three months, insiders sold 61,403 shares of company stock worth $1,582,774. 15.40% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. RA Capital Management L.P. raised its position in Tyra Biosciences by 43.9% during the 1st quarter. RA Capital Management L.P. now owns 10,416,609 shares of the company's stock valued at $170,832,000 after purchasing an additional 3,180,155 shares during the last quarter. BVF Inc. IL raised its position in shares of Tyra Biosciences by 70.1% in the 1st quarter. BVF Inc. IL now owns 4,661,194 shares of the company's stock worth $76,444,000 after acquiring an additional 1,921,599 shares in the last quarter. Perceptive Advisors LLC raised its position in shares of Tyra Biosciences by 50.5% in the 2nd quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company's stock worth $16,108,000 after acquiring an additional 338,208 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Tyra Biosciences by 18.6% in the 1st quarter. Vanguard Group Inc. now owns 899,800 shares of the company's stock worth $14,757,000 after acquiring an additional 140,833 shares in the last quarter. Finally, Kynam Capital Management LP raised its position in shares of Tyra Biosciences by 51.4% in the 1st quarter. Kynam Capital Management LP now owns 515,190 shares of the company's stock worth $8,449,000 after acquiring an additional 175,000 shares in the last quarter. Institutional investors own 84.14% of the company's stock.
About Tyra Biosciences
(
Get Free Report)
Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Read More
Before you consider Tyra Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tyra Biosciences wasn't on the list.
While Tyra Biosciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
